In Vitro Characterization of the Anti-Bacterial Activity of SQ109 against Helicobacter pylori

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Makobongo, Morris O ^a   Einck, Leo ^b   Peek, Richard M ^c   Merrell, D Scott ^a  

^a Uniformed Services University of the Health Sciences   (United States)

^b SEQUELLA INC   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CHLORAMPHENICOL; CLARITHROMYCIN; METRONIDAZOLE; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; RIFAMPICIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL GROWTH; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM CULTURE; BACTERIUM ISOLATE; BROTH DILUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG POTENTIATION; DRUG SYNTHESIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; IN VITRO STUDY; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; THERMOSTABILITY;

BACTERIA (MICROORGANISMS); HELICOBACTER; HELICOBACTER PYLORI; RATTUS;

ADAMANTANE; AMOXICILLIN; ANTITUBERCULAR AGENTS; CELL MEMBRANE; CHLORAMPHENICOL; CLARITHROMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; DUODENAL ULCER; DUODENITIS; ETHYLENEDIAMINES; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; HYDROGEN-ION CONCENTRATION; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON; STOMACH ULCER;

EID: 84880764384     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068917     Document Type: Article

References (74)

1. Brown LM, (2000) Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev 22: 283-297. doi:10.1093/oxfordjournals.epirev.a018040. PubMed: 11218379.
2. Torres J, Leal-Herrera Y, Perez-Perez G, Gomez A, Camorlinga-Ponce M, et al. (1998) A community-based seroepidemiologic study of Helicobacter pylori infection in Mexico. J Infect Dis 178: 1089-1094. doi:10.1086/515663. PubMed: 9806039.
3. Meurer LN, Bower DJ, (2002) Management of Helicobacter pylori infection. Am Fam Physician 65: 1327-1336. PubMed: 11996414.
4. Sobala GM, Crabtree JE, Dixon MF, Schorah CJ, Taylor JD, et al. (1991) Acute Helicobacter pylori infection: clinical features, local and systemic immune response, gastric mucosal histology, and gastric juice ascorbic acid concentrations. Gut 32: 1415-1418. doi:10.1136/gut.32.11.1415. PubMed: 1752479.
5. Suerbaum S, Michetti P, (2002) Helicobacter pylori infection. N Engl J Med 347: 1175-1186. doi:10.1056/NEJMra020542. PubMed: 12374879.
6. Graham DY, Hepps KS, Ramirez FC, Lew GM, Saeed ZA, (1993) Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol 28: 939-942. doi:10.3109/00365529309098288. PubMed: 8284627.
7. Treiber G, Lambert JR, (1998) The impact of Helicobacter pylori eradication on peptic ulcer healing. Am J Gastroenterol 93: 1080-1084. doi:10.1111/j.1572-0241.1998.00333.x. PubMed: 9672334.
8. Matsuzaki J, Suzuki H, Nishizawa T, Hirata K, Tsugawa H, et al. (2011) Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies. Antimicrob Agents Chemother.
9. Gisbert JP, (2011) Rescue therapy after Helicobacter pylori eradication failure. Gastroenterol Hepatol 34: 89-99. doi:10.1016/S0210-5705(11)70014-0.
10. Rokkas T, Sechopoulos P, Robotis J, Pistiolas D, (2006) Triple levofloxacin-based rescue therapy is an accepted empirical third-line treatment. Am J Gastroenterol 101: 1938-1939. doi:10.1111/j.1572-0241.2006.00684_2.x. PubMed: 16928256.
11. Gisbert JP, (2008) "Rescue" regimens after Helicobacter pylori treatment failure. World J Gastroenterol 14: 5385-5402. doi:10.3748/wjg.14.5385. PubMed: 18803350.
12. Mégraud F, (2004) H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 53: 1374-1384. doi:10.1136/gut.2003.022111. PubMed: 15306603.
13. Belhoussine-Idrissi L, Boedeker EC, (2002) Helicobacter pylori infection: treatment. Curr Opin Gastroenterol 18: 26-33. doi:10.1097/00001574-200201000-00005. PubMed: 17031226.
14. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, et al. (2007) Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56: 772-781. doi:10.1136/gut.2006.101634. PubMed: 17170018.
15. Projan SJ, (2003) Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 6: 427-430. doi:10.1016/j.mib.2003.08.003. PubMed: 14572532.
16. Nathan C, (2004) Antibiotics at the crossroads. Nature 431: 899-902. doi:10.1038/431899a. PubMed: 15496893.
17. Piddock LJ, (2011) The crisis of no new antibiotics-what is the way forward? Lancet Infect Dis.
18. Baltz RH, (2006) Molecular engineering approaches to peptide, polyketide and other antibiotics. Nat Biotechnol 24: 1533-1540. doi:10.1038/nbt1265. PubMed: 17160059.
19. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL, (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6: 29-40. doi:10.1038/nrd2201. PubMed: 17159923.
20. Marchese A, Schito GC, (2001) The oxazolidinones as a new family of antimicrobial agent. Clin Microbiol Infect 7 (Suppl 4):: 66-74. doi:10.1046/j.1469-0691.2001.00060.x. PubMed: 11688536.
21. Diekema DI, Jones RN, (2000) Oxazolidinones: a review. Drugs 59: 7-16. doi:10.2165/00003495-200059010-00002. PubMed: 10718097.
22. Mukhtar TA, Koteva KP, Wright GD, (2005) Chimeric streptogramin-tyrocidine antibiotics that overcome streptogramin resistance. Chem Biol 12: 229-235.
23. Mukhtar TA, Wright GD, (2005) Streptogramins, oxazolidinones, and other inhibitors of bacterial protein synthesis. Chem Rev 105: 529-542. doi:10.1021/cr030110z. PubMed: 15700955.
24. Protopopova M, Hanrahan C, Nikonenko B, Samala R, Chen P, et al. (2005) Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother 56: 968-974. doi:10.1093/jac/dki319. PubMed: 16172107.
25. Jia L, Tomaszewski JE, Hanrahan C, Coward L, Noker P, et al. (2005) Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br J Pharmacol 144: 80-87. PubMed: 15644871.
26. Chen P, Gearhart J, Protopopova M, Einck L, Nacy CA, (2006) Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J Antimicrob Chemother 58: 332-337. doi:10.1093/jac/dkl227. PubMed: 16751637.
27. Nikonenko BV, Protopopova M, Samala R, Einck L, Nacy CA, (2007) Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrob Agents Chemother 51: 1563-1565. doi:10.1128/AAC.01326-06. PubMed: 17242141.
28. Horwith G, Einck L, Protopopova M, Nacy C, (2007) Phase 1 safety and pharmacokinetics of SQ109, a new diamine antituberculosis drug. Meeting Abstract, 45th IDSA Annual Meeting, 2007 Oct 4-7; San Diego, CA, USA. Rockville, MD: Sequella, Inc.
29. National, Institute, of, Allergy, and, et al. (2010) Dose escalation Study of SQ109 in healthy adult volunteers US National Institutes of Health, ClinicalTrials.gov NCT00866190. Available: http://www.clinicaltrials.gov [Accessed 28 Jun 2010].
30. Jia L, Noker PE, Coward L, Gorman GS, Protopopova M, et al. (2006) Interspecies pharmacokinetics and in vitro metabolism of SQ109. Br J Pharmacol 147: 476-485. doi:10.1038/sj.bjp.0706650. PubMed: 16432511.
31. Makobongo MO, Kovachi T, Gancz H, Mor A, Merrell DS, (2009) In vitro antibacterial activity of acyl-lysyl oligomers against Helicobacter pylori. Antimicrob Agents Chemother 53: 4231-4239. doi:10.1128/AAC.00510-09. PubMed: 19620333.
32. Tahlan K, Wilson R, Kastrinsky DB, Arora K, Nair V, et al. (2012) SQ109 Targets MmpL3 a membrane transporter of trehalose tonomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother 56(4):1797-809.
33. Makobongo MO, Gancz H, Carpenter BM, McDaniel DP, Merrell DS, (2012) The oligo-acyl lysyl antimicrobial peptide C12K-2β 12 exhibits a dual mechanism of action and demonstrates strong in vivo efficacy against Helicobacter pylori. Antimicrob Agents Chemother 56: 378-390. doi:10.1128/AAC.00689-11. PubMed: 22064541.
34. Suerbaum S, Smith JM, Bapumia K, Morelli G, Smith NH, et al. (1998) Free recombination within Helicobacter pylori. Proc Natl Acad Sci U S A 95: 12619-12624. doi:10.1073/pnas.95.21.12619. PubMed: 9770535.
35. Björkholm B, Sjölund M, Falk PG, Berg OG, Engstrand L, et al. (2001) Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori. Proc Natl Acad Sci U S A 98: 14607-14612. doi:10.1073/pnas.241517298. PubMed: 11717398.
36. Millar MR, Pike J, (1992) Bactericidal activity of antimicrobial agents against slowly growing Helicobacter pylori. Antimicrob Agents Chemother 36: 185-187. doi:10.1128/AAC.36.1.185. PubMed: 1590687.
37. Beste DJ, Espasa M, Bonde B, Kierzek AM, Stewart GR, et al. (2009) The genetic requirements for fast and slow growth in mycobacteria. PLOS ONE 4: e5349. doi:10.1371/journal.pone.0005349. PubMed: 19479006.
38. Loh B, Grant C, Hancock RE, (1984) Use of the fluorescent probe 1-N-phenylnaphthylamine to study the interactions of aminoglycoside antibiotics with the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother 26: 546-551. doi:10.1128/AAC.26.4.546. PubMed: 6440475.
39. Hancock RE, Wong PG, (1984) Compounds which increase the permeability of the Pseudomonas aeruginosa outer membrane. Antimicrob Agents Chemother 26: 48-52. doi:10.1128/AAC.26.1.48. PubMed: 6433788.
40. Ahmed N, Sechi LA, (2005) Helicobacter pylori and gastroduodenal pathology: new threats of the old friend. Ann Clin Microbiol Antimicrob 4: 1. doi:10.1186/1476-0711-4-1. PubMed: 15634357.
41. Chuah SK, Tsay FW, Hsu PI, Wu DC, (2011) A new look at anti-Helicobacter pylori therapy. World J Gastroenterol 17: 3971-3975. doi:10.3748/wjg.v17.i35.3971. PubMed: 22046084.
42. Fakheri H, Taghvaei T, Hosseini V, Bari Z, (2012) A Comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: A randomized clinical trial. Helicobacter 17: 43-48. doi:10.1111/j.1523-5378.2011.00896.x. PubMed: 22221615.
43. Oh HS, Lee DH, Seo JY, Cho YR, Kim N, et al. (2011) Ten-day sequential therapy is more effective than proton-pump inhibitor-based therapy in Korea: a prospective randomized study. J Gastroenterol Hepatol.
44. Park HG, Jung MK, Jung JT, Kwon JG, Kim EY, et al. (2012) Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naive patients. Aliment Pharmacol Ther 35: 56-65. doi:10.1111/j.1365-2036.2011.04902.x. PubMed: 22066530.
45. Ables AZ, Simon I, Melton ER, (2007) Update on Helicobacter pylori treatment. Am Fam Physician 75: 351-358. PubMed: 17304866.
46. Malfertheiner P, (1993) Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment. Scand J Gastroenterol Suppl 196: 34-37. PubMed: 8341989.
47. Amieva MR, Salama NR, Tompkins LS, Falkow S, (2002) Helicobacter pylori enter and survive within multivesicular vacuoles of epithelial cells. Cell Microbiol 4: 677-690. doi:10.1046/j.1462-5822.2002.00222.x. PubMed: 12366404.
48. Semino-Mora C, Doi SQ, Marty A, Simko V, Carlstedt I, et al. (2003) Intracellular and interstitial expression of Helicobacter pylori virulence genes in gastric precancerous intestinal metaplasia and adenocarcinoma. J Infect Dis 187: 1165-1177. doi:10.1086/368133. PubMed: 12695995.
49. Dubois A, (2007) Intracellular Helicobacter pylori and gastric carcinogenesis: an "old" frontier worth revisiting. Gastroenterology 132: 1177-1180. doi:10.1053/j.gastro.2007.01.068. PubMed: 17383438.
50. Kearney DJ, (2001) Retreatment of Helicobacter pylori infection after initial treatment failure. Am J Gastroenterol 96: 1335-1339. doi:10.1111/j.1572-0241.2001.03788.x. PubMed: 11374665.
51. Gisbert JP, Bermejo F, Castro-Fernández M, Pérez-Aisa A, Fernández-Bermejo M, et al. (2008) Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am J Gastroenterol 103: 71-76. doi:10.1111/j.1572-0241.2007.01500.x. PubMed: 17764498.
52. van den Boogaard J, Kibiki GS, Kisanga ER, Boeree MJ, Aarnoutse RE, (2009) New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother 53: 849-862. doi:10.1128/AAC.00749-08. PubMed: 19075046.
53. Sánchez F, López Colomés JL, Villarino E, Grosset J, (2011) New drugs for tuberculosis treatment. Enferm Infecc Microbiol Clin 29 (Suppl 1):: 47-56. doi:10.1016/S0213-005X(11)70018-0. PubMed: 21420567.
54. Jia L, Coward L, Gorman GS, Noker PE, Tomaszewski JE, (2005) Pharmacoproteomic effects of isoniazid, ethambutol, and N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine (SQ109) on Mycobacterium tuberculosis H37Rv. J Pharmacol Exp Ther 315: 905-911. doi:10.1124/jpet.105.087817. PubMed: 16085758.
55. Stratton CW, Aldridge KE, Gelfand MS, (1995) In vitro killing of penicillin-susceptible,-intermediate, and-resistant strains of Streptococcus pneumoniae by cefotaxime, ceftriaxone, and ceftizoxime: a comparison of bactericidal and inhibitory activity with achievable CSF levels. Diagn Microbiol Infect Dis 22: 35-42. doi:10.1016/0732-8893(95)00094-Q. PubMed: 7587048.
56. Han SR, Bhakdi S, Maeurer MJ, Schneider T, Gehring S, (1999) Stable and unstable amoxicillin resistance in Helicobacter pylori: should antibiotic resistance testing be performed prior to eradication therapy? J Clin Microbiol 37: 2740-2741. PubMed: 10405437.
57. Kim JM, Kim JS, Jung HC, Kim N, Kim YJ, et al. (2004) Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob Agents Chemother 48: 4843-4847. doi:10.1128/AAC.48.12.4843-4847.2004. PubMed: 15561865.
58. Lee RE, Protopopova M, Crooks E, Slayden RA, Terrot M, et al. (2003) Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J Comb Chem 5: 172-187. doi:10.1021/cc020071p. PubMed: 12625709.
59. Guy ES, Mallampalli A, (2008) Managing TB in the 21st century: existing and novel drug therapies. Ther Adv Respir Dis 2: 401-408. doi:10.1177/1753465808099522. PubMed: 19124385.
60. Rotem S, Radzishevsky IS, Bourdetsky D, Navon-Venezia S, Carmeli Y, et al. (2008) Analogous oligo-acyl-lysines with distinct antibacterial mechanisms. FASEB J 22: 2652-2661. doi:10.1096/fj.07-105015. PubMed: 18385215.
61. Tiyanont K, Doan T, Lazarus MB, Fang X, Rudner DZ, et al. (2006) Imaging peptidoglycan biosynthesis in Bacillus subtilis with fluorescent antibiotics. Proc Natl Acad Sci U S A 103: 11033-11038. doi:10.1073/pnas.0600829103. PubMed: 16832063.
62. Takacs CN, Poggio S, Charbon G, Pucheault M, Vollmer W, et al. (2010) MreB drives de novo rod morphogenesis in Caulobacter crescentus via remodeling of the cell wall. J Bacteriol 192: 1671-1684. doi:10.1128/JB.01311-09. PubMed: 20023035.
63. Ouellette SP, Karimova G, Subtil A, Ladant D, (2012) Chlamydia co-opts the rod shape-determining proteins MreB and Pbp2 for cell division. Mol Microbiol 85: 164-178. doi:10.1111/j.1365-2958.2012.08100.x. PubMed: 22624979.
64. Hakenbeck R, König A, Kern I, van der Linden M, Keck W, et al. (1998) Acquisition of five high-Mr penicillin-binding protein variants during transfer of high-level beta-lactam resistance from Streptococcus mitis to Streptococcus pneumoniae. J Bacteriol 180: 1831-1840. PubMed: 9537382.
65. Okamoto T, Yoshiyama H, Nakazawa T, Park ID, Chang MW, et al. (2002) A change in PBP1 is involved in amoxicillin resistance of clinical isolates of Helicobacter pylori. J Antimicrob Chemother 50: 849-856. doi:10.1093/jac/dkf140. PubMed: 12461003.
66. Calafatti SA, Ortiz RA, Deguer M, Martinez M, Pedrazzoli J Jr., (2001) Effect of acid secretion blockade by omeprazole on the relative bioavailability of orally administered furazolidone in healthy volunteers. Br J Clin Pharmacol 52: 205-209. doi:10.1046/j.0306-5251.2001.01435.x. PubMed: 11488780.
67. Chu YT, Wang YH, Wu JJ, Lei HY, (2010) Invasion and multiplication of Helicobacter pylori in gastric epithelial cells and implications for antibiotic resistance. Infect Immun 78: 4157-4165. doi:10.1128/IAI.00524-10. PubMed: 20696835.
68. Wang YH, Wu JJ, Lei HY, (2009) When Helicobacter pylori invades and replicates in the cells. Autophagy 5: 540-542. doi:10.4161/auto.5.4.8167. PubMed: 19270492.
69. Baltrus DA, Amieva MR, Covacci A, Lowe TM, Merrell DS, et al. (2009) The complete genome sequence of Helicobacter pylori strain G27. J Bacteriol 191: 447-448. doi:10.1128/JB.01416-08. PubMed: 18952803.
70. Franco AT, Israel DA, Washington MK, Krishna U, Fox JG, et al. (2005) Activation of beta-catenin by carcinogenic Helicobacter pylori. Proc Natl Acad Sci U S A 102: 10646-10651. doi:10.1073/pnas.0504927102. PubMed: 16027366.
71. Oh JD, Kling-Bäckhed H, Giannakis M, Xu J, Fulton RS, et al. (2006) The complete genome sequence of a chronic atrophic gastritis Helicobacter pylori strain: evolution during disease progression. Proc Natl Acad Sci U S A 103: 9999-10004. doi:10.1073/pnas.0603784103. PubMed: 16788065.
72. Lee A, O'Rourke J, De Ungria MC, Robertson B, Daskalopoulos G, et al. (1997) A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology 112: 1386-1397. doi:10.1016/S0016-5085(97)70155-0. PubMed: 9098027.
73. Alm RA, Ling LS, Moir DT, King BL, Brown ED, et al. (1999) Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature 397: 176-180. doi:10.1038/16495. PubMed: 9923682.
74. Tomb JF, White O, Kerlavage AR, Clayton RA, Sutton GG, et al. (1997) The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 388: 539-547. doi:10.1038/41483. PubMed: 9252185.